1-3 of 3
Jan M.A. Van Tornout
Close
Sort by
Journal Articles

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).

Kimmo Porkka, MD, Bengt Simonsson, MD, Herve Dombret, MD, Giovanni Martinelli, MD, Oliver G. Ottmann, MD, Chao Zhu, Jan M.A. Van Tornout, MD, Felix T. Garzon, MD, Richard A. Larson, MD
Journal: Blood
Blood (2007) 110 (11): 2810.
https://doi.org/10.1182/blood.V110.11.2810.2810
Published: 2007
Journal Articles

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).

Francois Guilhot, MD, Jane F. Apperley, MD, Dong-Wook Kim, MD, Gianantonio Rosti, MD, Xiaobin Yuan, Jan M.A. Van Tornout, MD, Felix T. Garzon, MD, Jorge Cortes, MD
Journal: Blood
Blood (2007) 110 (11): 470.
https://doi.org/10.1182/blood.V110.11.470.470
Published: 2007
Journal Articles

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.

Carlo Gambacorti, Jorge Cortes, Dong-Wook Kim, Herve Dombret, Chao Zhu, Jan M.A. Van Tornout, Felix T. Garzon, Michele Baccarani
Journal: Blood
Blood (2007) 110 (11): 472.
https://doi.org/10.1182/blood.V110.11.472.472
Published: 2007